This course has expired. You can still review the content but course credit is no longer available.
The introduction of anti-VEGF agents for the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO), transformed the management of these conditions. While the clinical benefits of these compounds are well documented their use brings up other issues for ophthalmologists, namely, cost. Thus, payers have become more involved in managing the use of these agents, potentially interfering with clinical decision making. This live event brings together thought leaders in the retina field to discuss the challenges they face in obtaining access to anti-VEGF medications for their patients, and how they overcome those challenges.
Supported through an educational grant from Regeneron Pharmaceuticals, Inc.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve Medical Education LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
David Eichenbaum, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:Alimera Sciences; Allergan plc; Genentech; Notal Vision; and Regeneron Pharmaceuticals, Inc. Grant/Research Support:Alcon/Novartis; Allergan plc.; Clearside Biomedical; Genentech; and Opthotech. Speaker’s Bureau: Allergan plc; Genentech; and Notal Vision. Stock/Shareholder: BIRC, Clearside Biomedical; Humera; and US Retina.
Dante Pieramici, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro; Genentech, Inc.; Kodiac; Novartis; Regeneron Pharmaceuticals. Grant/Research Support: Aerpio Therapeutics; Allegro Ophthalmics; Genentech, Inc.; Novartis; Ophthea; Regeneron Pharmaceuticals; Regenxbio; and RPE Patch.
Ankoor R. Shah, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board: Allergan.
Editorial Support Disclosures, Erin K. Fletcher, MIT, director of compliance and education, Evolve; Susan Gallagher-Pecha, director of client services and project management, Evolve; and Debra Gordon, MS, writer, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.